{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T21:10:18Z","timestamp":1758748218775,"version":"3.44.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["advancessurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Surgery"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.yasu.2020.03.001","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T08:01:59Z","timestamp":1589356919000},"page":"191-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Management of Melanoma Patients with Positive Nodes"],"prefix":"10.1016","volume":"54","author":[{"given":"Rachel M.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A.","family":"Delman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.yasu.2020.03.001_bib1","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.yasu.2020.03.001_bib2","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"10.1016\/j.yasu.2020.03.001_bib3","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1200\/JCO.2016.71.9393","article-title":"Conditional survival: an assessment of the prognosis of patients at time points after initial diagnosis and treatment of locoregional melanoma metastasis","volume":"35","author":"Haydu","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.yasu.2020.03.001_bib4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.soc.2014.12.005","article-title":"Lymph node dissection for stage III melanoma","volume":"24","author":"Diller","year":"2015","journal-title":"Surg Oncol Clin N Am"},{"issue":"4","key":"10.1016\/j.yasu.2020.03.001_bib5","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/SLA.0b013e318161312a","article-title":"Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma","volume":"247","author":"Guggenheim","year":"2008","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.yasu.2020.03.001_bib6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/jso.20084","article-title":"Lessons learned from the Sunbelt Melanoma Trial","volume":"86","author":"McMasters","year":"2004","journal-title":"J\u00a0Surg Oncol"},{"issue":"3","key":"10.1016\/j.yasu.2020.03.001_bib7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/01.sla.0000181092.50141.fa","article-title":"Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial","volume":"242","author":"Morton","year":"2005","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.yasu.2020.03.001_bib8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/jso.25316","article-title":"Current management of regional lymph nodes in patients with melanoma","volume":"119","author":"Bartlett","year":"2019","journal-title":"J\u00a0Surg Oncol"},{"author":"National Comprehensive Cancer Network","key":"10.1016\/j.yasu.2020.03.001_bib9"},{"issue":"8","key":"10.1016\/j.yasu.2020.03.001_bib10","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.ejso.2017.05.014","article-title":"Melanoma patient imaging in the era of effective systemic therapies","volume":"43","author":"Stodell","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.yasu.2020.03.001_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jnci\/djq455","article-title":"Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis","volume":"103","author":"Xing","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.yasu.2020.03.001_bib12","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/0360-3016(86)90005-2","article-title":"Arm lymphedema in patients treated conservatively for breast cancer: relationship to patient age and axillary node dissection technique","volume":"12","author":"Pezner","year":"1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.yasu.2020.03.001_bib13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/bjs.4372","article-title":"Randomized clinical trial comparing level II and level III axillary node dissection in addition to mastectomy for breast cancer","volume":"91","author":"Tominaga","year":"2004","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.yasu.2020.03.001_bib14","first-page":"141","article-title":"Axillary lymph node metastases of melanoma: management of third-level nodes","volume":"30","author":"Gentile","year":"2016","journal-title":"In\u00a0Vivo"},{"issue":"9","key":"10.1016\/j.yasu.2020.03.001_bib15","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1245\/s10434-019-07509-2","article-title":"Utility of level III axillary node dissection in melanoma patients with palpable axillary lymph node disease","volume":"26","author":"Mahvi","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.yasu.2020.03.001_bib16","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1245\/s10434-013-2880-2","article-title":"How often do level III nodes bear melanoma metastases and does it affect patient outcomes?","volume":"20","author":"Nessim","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.yasu.2020.03.001_bib17","doi-asserted-by":"crossref","first-page":"S1172","DOI":"10.1245\/s10434-015-4602-4","article-title":"Risk factors for positive deep pelvic nodal involvement in patients with palpable groin melanoma metastases: can the extent of surgery be safely minimized? : A retrospective, multicenter cohort study","volume":"22","author":"Oude Ophuis","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.yasu.2020.03.001_bib18","first-page":"209","article-title":"The value of Cloquet's node in predicting melanoma nodal metastases in the pelvic lymph node basin","volume":"8","author":"Strobbe","year":"2001","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.yasu.2020.03.001_bib19","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1245\/s10434-007-9512-7","article-title":"Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma","volume":"14","author":"Badgwell","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.yasu.2020.03.001_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF02303564","article-title":"Groin dissection in malignant melanoma","volume":"1","author":"Karakousis","year":"1994","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.yasu.2020.03.001_bib21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/CMR.0000000000000109","article-title":"Pelvic lymph node status prediction in melanoma patients with inguinal lymph node metastasis","volume":"24","author":"Pasquali","year":"2014","journal-title":"Melanoma Res"},{"issue":"12","key":"10.1016\/j.yasu.2020.03.001_bib22","first-page":"A4953","article-title":"Recurrence and survival after neck dissections in cutaneous head and neck melanoma","volume":"61","author":"Andersen","year":"2014","journal-title":"Dan Med J"},{"issue":"12","key":"10.1016\/j.yasu.2020.03.001_bib23","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1245\/s10434-018-6692-2","article-title":"Treatment of Clinically Positive Cervical Lymph Nodes by Limited Local Node Excision and Adjuvant Radiotherapy in Melanoma Patients with Major Comorbidities","volume":"25","author":"Kroon","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.yasu.2020.03.001_bib24","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","article-title":"Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial","volume":"16","author":"Henderson","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.yasu.2020.03.001_bib25","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamasurg.2013.1335","article-title":"Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result","volume":"148","author":"Jones","year":"2013","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.yasu.2020.03.001_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/CMR.0000000000000211","article-title":"Predictors and patterns of melanoma recurrence following a negative sentinel lymph node biopsy","volume":"26","author":"O'Connell","year":"2016","journal-title":"Melanoma Res"},{"issue":"7","key":"10.1016\/j.yasu.2020.03.001_bib27","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1245\/s10434-019-07369-w","article-title":"Recurrence of melanoma after a negative sentinel node biopsy: predictors and impact of recurrence site on survival","volume":"26","author":"Thomas","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.yasu.2020.03.001_bib28","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/01.PRS.0000070989.23469.1F","article-title":"Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma","volume":"112","author":"Wagner","year":"2003","journal-title":"Plast Reconstr Surg"},{"issue":"5","key":"10.1016\/j.yasu.2020.03.001_bib29","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1245\/s10434-006-9267-6","article-title":"Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes","volume":"14","author":"Zogakis","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"23","key":"10.1016\/j.yasu.2020.03.001_bib30","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"36","key":"10.1016\/j.yasu.2020.03.001_bib31","doi-asserted-by":"crossref","first-page":"e1433","DOI":"10.1097\/MD.0000000000001433","article-title":"Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients","volume":"94","author":"Kretschmer","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.yasu.2020.03.001_bib32","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1245\/s10434-014-4356-4","article-title":"Patterns of Recurrence in Patients with Stage IIIB\/C Cutaneous Melanoma of the Head and Neck Following Surgery With and Without Adjuvant Radiation Therapy: Is Isolated Regional Recurrence Salvageable?","volume":"22","author":"Barbour","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.yasu.2020.03.001_bib33","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/jso.24939","article-title":"Neoadjuvant systemic therapy for regionally advanced melanoma","volume":"117","author":"Jakub","year":"2018","journal-title":"J\u00a0Surg Oncol"},{"issue":"2","key":"10.1016\/j.yasu.2020.03.001_bib34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial","volume":"19","author":"Amaria","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.yasu.2020.03.001_bib35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00008390-199812000-00010","article-title":"Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases","volume":"8","author":"Buzaid","year":"1998","journal-title":"Melanoma Res"},{"issue":"2","key":"10.1016\/j.yasu.2020.03.001_bib36","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/cncr.10186","article-title":"A\u00a0phase II study of neoadjuvant biochemotherapy for stage III melanoma","volume":"94","author":"Gibbs","year":"2002","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.yasu.2020.03.001_bib37","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1200\/JCO.2005.04.5344","article-title":"Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma","volume":"24","author":"Lewis","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.yasu.2020.03.001_bib38","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1200\/JCO.2005.05.2498","article-title":"Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses","volume":"24","author":"Moschos","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.yasu.2020.03.001_bib39","doi-asserted-by":"crossref","first-page":"e1231291","DOI":"10.1080\/2162402X.2016.1231291","article-title":"Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit","volume":"6","author":"Tarhini","year":"2017","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.yasu.2020.03.001_bib40","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.yasu.2020.03.001_bib41","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.yasu.2020.03.001_bib42","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jso.25352","article-title":"Neoadjuvant treatments for advanced resectable melanoma","volume":"119","author":"Liu","year":"2019","journal-title":"J\u00a0Surg Oncol"},{"issue":"7","key":"10.1016\/j.yasu.2020.03.001_bib43","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","article-title":"Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF(V600) mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.yasu.2020.03.001_bib44","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","article-title":"Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium","volume":"20","author":"Amaria","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.yasu.2020.03.001_bib45","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1245\/s10434-017-6267-7","article-title":"Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update","volume":"25","author":"Wong","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10.1016\/j.yasu.2020.03.001_bib46","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa060992","article-title":"Sentinel-node biopsy or nodal observation in melanoma","volume":"355","author":"Morton","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.yasu.2020.03.001_bib47","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.2015.63.3776","article-title":"Final results of the sunbelt melanoma trial: a multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy","volume":"34","author":"McMasters","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.yasu.2020.03.001_bib48","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1001\/jamasurg.2018.1516","article-title":"Completion node dissection after sentinel node biopsy in melanoma","volume":"153","author":"Delman","year":"2018","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.yasu.2020.03.001_bib49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1245\/s10434-019-07830-w","article-title":"The landmark series: MSLT-1, MSLT-2 and DeCOG (management of lymph nodes)","volume":"27","author":"Bello","year":"2020","journal-title":"Ann Surg Oncol"}],"container-title":["Advances in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065341120300014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065341120300014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T20:31:02Z","timestamp":1758745862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065341120300014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":49,"alternative-id":["S0065341120300014"],"URL":"https:\/\/doi.org\/10.1016\/j.yasu.2020.03.001","relation":{},"ISSN":["0065-3411"],"issn-type":[{"type":"print","value":"0065-3411"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Melanoma Patients with Positive Nodes","name":"articletitle","label":"Article Title"},{"value":"Advances in Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yasu.2020.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}